Market Analysis of Hypoglycemic Drugs 'Sulfonylurea'

Sulfonylurea hypoglycemic drugs are the most widely used type of hypoglycemic drugs in clinical practice, have a relatively long history, and have now developed into the third generation. The main mechanisms of action include: stimulating insulin secretion, increasing the sensitivity of surrounding tissues to insulin, and reducing the production of hepatic glycogen. The main representative varieties are: gliclazide (second generation), glipizide (second generation), glimepiride (third generation), these three varieties are included in the national centralized collection, among which the Chinese The second batch of glimepiride tablets and the fourth batch of gliclazide sustained-release tablets, due to the sharp drop in price, the overall amount of the scale has shrunk rapidly. Glipizide tablets and controlled-release tablets have been included in 5 batches of national procurement and have been implemented in the fourth quarter of 2021.

It is worth noting that a total of 5 companies were selected for glimepiride included in the second batch of centralized procurement in the country. Among them, Guizhou Shengjitang Pharmaceutical Co., Ltd. obtained the largest centralized procurement supply at the lowest price. In January 2022 , due to "the company has serious defects in plant maintenance, equipment cleaning, stability inspection, etc., and it is comprehensively judged that the company does not meet the quality management standards for drug production", it was disqualified from the selection, and it was included in the "violation list". Its supply area Will be replaced by other selected manufacturers. This incident is the first time that an enterprise that is implementing the selection agreement failed to pass the inspection of the drug regulatory department. Although no product substandardness was found in the sampling inspection of the company's production site and distribution links, and no abnormality was found in the adverse reaction monitoring, the drug regulatory department did not find any abnormality. Comprehensive research and judgment determined that the enterprise did not meet the quality management standards for drug production, and took risk control measures in accordance with the "four strictest" requirements, and was disqualified by the medical insurance department.